Trimodality Approach to Localized Prostate Cancer: Pembrolizumab, ADT, and SBRT Followed by Prostatectomy
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This study will enroll prostate cancer patients with an unfavorable diagnosis. Subjects will
receive a combination of pembrolizumab, Stereotactic Body Radiation Therapy (SBRT) to the
prostate, and short-term androgen deprivation therapy (STADT or Short-term ADT). After
receiving this "trimodal therapy", subjects will undergo a radical prostatectomy. The
prostate tissue will be analyzed for differences in pathology and local immune cell
infiltration, and subjects will be followed for 2 years to watch for prostate specific
antigen (PSA) recurrence. The PSA results will be analyzed by comparing them to historical
controls that have already been published, to learn if this therapy approach delays PSA rise.